Phospho serine and threonine analysis of normal and mutated granulocyte colony stimulating factor receptors

Pankaj Dwivedi1, David E. Muench2, Michael Wagner3, Mohammad Azam4, H. Leighton Grimes2,4 & Kenneth D. Greis1

Granulocyte colony stimulating factor receptor (G-CSFR) plays an important role in the production of neutrophil granulocytes. Mutated G-CSFRs have been directly associated with two distinct malignant phenotypes in patients, e.g. acute myeloid leukemia (AML) and chronic neutrophilic leukemia (CNL). However, the signaling mechanism of the mutated G-CSFRs is not well understood. Here, we present a comprehensive SILAC-based quantitative phosphoserine and phosphothreonine dataset of the normal and mutated G-CSFRs signaling using the BaF3 cell-line-based in vitro model system. High pH reversed phase concatenation and Titanium Dioxide Spin Tip column were utilized to increase the dynamic range and detection of the phosphoproteome of G-CSFRs. The dataset was further analyzed using several computational tools to validate the quality of the dataset. Overall, this dataset is the first global phosphoproteomics analysis of both normal and disease-associated-mutant G-CSFRs. We anticipate that this dataset will have a strong potential to decipher the phospho-signaling differences between the normal and malignant G-CSFR biology with therapeutic implications. The phosphoproteomic dataset is available via the PRIDE partner repository.

Background & Summary
Granulocyte colony stimulating factor (G-CSF) also known as colony stimulating factor 3 (CSF3) is the primary ligand for granulocyte colony stimulating factor receptor (G-CSFR). G-CSFR is a transmembrane cytokine receptor consisting of extracellular, transmembrane and intracellular domains. There are a number of myeloid disorders that have been related to the mutations in CSF3R including Severe Congenital Neutropenia (SCN), Chronic Neutrophilic Leukemia (CNL), Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), atypical Chronic Myelogenous Leukemia (aCML). SCN patients treated with G-CSF (in the form of induction therapy) regain sufficient levels of neutrophils to reduce infection related mortality; however, a major concern is the leukemic progression of SCN into MDS or AML. Specifically, SCN patients on G-CSF treatment can acquire somatic mutations in CSF3R, leading to truncation of the cytoplasmic region of G-CSFR. Other CSF3R mutations (specifically the proximal T618I point mutation) are frequently observed in CNL that is characterized by the constitutive activation of the receptor, leading to an excess of neutrophils.

Previous studies have shown a differential activation of JAK/STAT pathway downstream of WT and mutated receptor after G-CSF activation. However, the complete signaling biology of G-CSF activated receptor either in the normal or mutated condition is still not known. In the current study, a global profiling of changes in the phosphoproteome from WT, proximal (T618I) and truncated (Q741x) G-CSFR in response with G-CSF in a time dependent manner at 12.5 min (early time point), and 90 min (late time point) post G-CSF induction was performed (Figs 1–2). The workflow included the combination of SILAC labeling, trypsin digestion, pre-fractionation/enrichment to extract phosphotyrosines, high pH RP-chromatography (high-pHRPC), TiO2
enrichment of phospho-serine/threonine (pS/pT), high-resolution nano-LC-MS/MS analysis for phosphorylation changes and bioinformatics analyses (Fig. 1a–d). The selection of induction time points at 12.5 min (early) and 90 min (late—back to baseline) was based on a detailed induction time course to evaluate the phosphorylation dynamics of phospho-Stat5 in the WT and mutated receptor expressing cells8. Collectively, more than 10,000 unique phospho peptides (pS/pT) were identified. The phospho-tyrosine dataset for this study included about
Here, we present the pS/pT dataset with upward of 1,000 phosphorylation site changes, suggesting a highly dynamic network of cellular signaling that differs between the WT and mutant receptors. Furthermore, the short induction time (particularly for the 12.5 min time point) would strongly suggest that the comparative changes in phosphorylation are due to an increase or decrease in phosphorylation rather than changes in the total amount of a given protein. Given the lack of understating of the phosphorylation dynamics of G-CSFR signaling, this dataset has a great potential to provide the research community with opportunity to further explore normal and variant signaling through the G-CSFR. This dataset may also provide an avenue to understand the mechanism of how the clinically successful induction therapy for SCN patients transition to MDS and AML. Finally, better understanding of the signaling network associated with G-CSFR could also lead to new targets and impact alternative therapeutic strategies for SCN/AML and CNL patients.

**Methods**

**Reagents.** RPMI was used to culture the BaF3 cells with and without lysine and arginine, fetal bovine serum (FBS), L-glutamine, and antibiotics. Lysine, arginine, FBS, L-glutamine and antibiotics were purchased from Invitrogen (Carlsbad, CA). Heavy amino acids $^{13}$C$_6$-Lysine and $^{13}$C$_6$-Arginine, were obtained from Cambridge Isotope Laboratories (Andover, MA). For proteolytic digestion, TPCK-treated trypsin was used. TPCK-treated Trypsin was purchased from Worthington Biochemical Corp. (Lakewood, NJ). Titanium Dioxide Spin Tip columns were purchased from Thermo Scientific (# 88303). Anti-phospho-Stat3, anti-phospho-Stat5, anti-phospho-Erk antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-G-CSFR antibody was purchased from Abcam (Cambridge, MA). All other reagents used in this study were from Fisher Scientific (Pittsburgh, PA).

**Immunoblotting and phospho-kinase array.** The normal and mutated G-CSF receptors-expressing BaF3 cells were serum starved for 6 hours before G-CSF induction for various time points (ranging from 5 min to 180 min). The cells were washed with PBS followed by lysis in 20 mM Tris-HCl, 150 mM Sodium Chloride, 2 mM EDTA, 1 mM EGTA, Complete Mini Protease Inhibitor Cocktail Tablet (Roche), 10 mM Sodium fluoride, 1 mM Sodium orthovanadate, 1 mM beta-glycerophosphate, 1% NP-40, 1% Tween-20, 10% Glycerol, 2.5 mM Sodium pyrophosphate, 1 mM PMSE. The lysed cellular contents were further sonicated three times at 15 W of 15 sec each. The supernatant was collected post centrifugation at 20,000 $\times$ g for 10 min at 4 °C. The protein estimation was performed using 660 nm assay (Thermo Scientific, #22660). 25–30 µg of total lysates were used for each immunoblot analyses. 4–12% Bis Tris gel (Invitrogen, #NP0321) gradient SDS-PAGE gel was used for protein separation. PVDF membrane (Millipore, #PVIH00010) was used for protein transfer using a semi-dry apparatus at 15 V for 30 min. 5% milk solution in TBS-T (0.1% Tween-20, Invitrogen) was used for blocking the PVDF membrane. Phospho-Stat5 (Tyr 694) (C11C5) (#9359), Phospho-Stat3 (Tyr705) (D3A7) (#9145), Phospho-p44/p42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) (#4370), Stat5 (#9363), Stat3 (#4904), p44/42 MAPK (Erk1/2) (#9102), Actin (#4970) primary antibodies (from Cell Signaling Technologies) & G-CSFR primary antibody (ab126167, Abcam) were used for the immunoblot analyses. 1:1000 dilutions of primary antibodies were used in 5% BSA solution in TBS-T (0.1% Tween-20). Anti-rabbit and -mouse secondary antibodies from GE Healthcare were used at 1:5000 dilutions in 5% milk solution in TBS-T (0.1% Tween-20). All immunoblots were developed using ChemiDoc™ touch imaging system (Bio-Rad). This section is an expanded version of descriptions in our related manuscript.

For phospho kinase array analysis, vendor specific instructions were followed (R&D systems, # ARY003B). Briefly, ~10 million WT and mutant G-CSFRs expressing BaF3 cells were serum starved for 6 hours and stimulated with 40 ng/mL of G-CSF for 12.5 and 90 min. The stimulated cells were washed with 10 mL of ice cold PBS and lysed in 1 mL of lysis buffer provided with kinase array kit. All other wash and reaction steps were done as described in the assay kit using the supplied reagents. After the final wash of the reacted membranes, the chemi-luminescent readout was initiated by incubation with the supplied Chemi Reagent mixture for
Cell culture and SILAC labeling. BaF3 cell lines stably expressing normal and mutated G-CSFRs, were grown in RPMI medium (Invitrogen, Carlsbad, CA) with 5% fetal bovine serum (FBS), 2mM L-glutamine, 100U/mL penicillin and 100µg/mL streptomycin in a humidified incubator at 37 °C with 5.0% CO2. For heavy amino acid labeling, the cells were cultured in RPMI with 5% FBS, 2mM L-glutamine, 100U/mL penicillin and 100µg/mL streptomycin, 50mg/L arginine-13C6 monohydrochloride and 100mg/L lysine-13C6 monohydrochloride (light) or 50mg/L arginine-15N monohydrochloride and 100mg/L lysine-15N monohydrochloride (heavy) (Cambridge Isotope Laboratories). The heavy amino acid labeling efficiency was determined after 5 doublings of the cells by removing 1 million actively growing cells from each lysate by lysis, trypsin digestion and LC-MS analysis. Once the incorporation of heavy amino acids was confirmed to be more than 95%, the cells were collected by centrifugation at 1200 rpm for 5 min. Subsequently, the cells were washed 3 times with PBS, then re-suspended in serum free medium for 6 hours for serum starvation prior to G-CSF stimulation. Cells grown in heavy SILAC medium were stimulated with G-CSF (40 ng/mL) for 12.5 mins and 90 mins at 37 °C and cells grown in light medium were left unstimulated (Fig. 2). Each induction time point experiment was performed as two independent biological replicates (Fig. 2). This section is an expanded version of descriptions in our related manuscript.

Cell lysis and protein digestion. Post-G-CSF stimulated BaF3 cells were washed with cold PBS and lysed in 20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate. The lysed cells were further disrupted by sonication (15 W output with 3 bursts of 15 sec each). During sonication, cell lysates were cooled on ice for 1 min before each burst to avoid any protein denaturation. After sonication, the lysates were cleared by centrifugation at 20,000 × g at 15 °C for 20 min to capture the solubilized protein supernatant. The 660 nM protein assay (Thermo, #22660) was used to measure the total protein amount. 10 mg of light and heavy labeled protein for each pairwise comparison were mixed together before reduction and alkylation steps. The mixed lysate proteins were reduced with DTT at a final concentration of 5 mM at 60 °C for 20 min. Before alkylation, the reduced samples were cooled on ice until it reached room temperature (RT). Alkylation was performed using a final concentration of 10 mM iodoacetamide for 10 min at RT in the dark. Furthermore, the samples were diluted 5X in 20 mM HEPES pH 8.0 to reduce the final urea concentration to less than 2 M for trypsin digestion. TPCK-treated trypsin (Worthington Biochemical Corp) prepared as a stock in 1 mM HCl, was added at a 1:50 (w/w) ratio (trypsin/protein) to the reduced and alkylate lysates for overnight proteolytic digestion at room temperature while rotating. Finally, the peptide mixture was acidified to final concentration of 1% Trifluoroacetic acid (TFA) to stop the reaction. This section is an expanded version of descriptions in our related manuscript.

Sep-Pak C18 desalting of lysate peptides. The acidified peptide solution was centrifuged at 1780 × g at RT for 15 min to remove any precipitate. Desalting was done using C-18 Sep-Pak cartridges (Waters, cat# WAT051910). The Sep-Pak columns were washed with a total of 10 mL of 0.1% TFA prior to the peptide loading. The acidified and cleared peptide solution was loaded on Sep-Pak column using gravity flow. Once loading was finished, the column was washed with 10 mL of 0.1% TFA. Peptide elution was performed using a 2 mL of 40% acetonitrile in 0.1% TFA solution. The elution step was repeated three times and all the eluate were combined at the end. The eluted peptides were lyophilized for at least 3 days, reconstituted in 1.4 mL of immuno affinity buffer (20 mM Tris-HCL, 10 mM Sodium Phosphate, 50 mM Sodium Chloride, pH 7.4) and subjected to phosphotyrosine capture using pY1000 cartridges from Cell Signaling Technologies (#8803) using the vendor supplied instructions. The flow through and wash from the phospho-tyrosine enrichment was collected, frozen, lyophilized in a SpeedVac and stored at −80°C until further analysis. This section is an expanded version of descriptions in our related manuscript.

High-pH reversed-phase liquid chromatography (high-pHRPLC) and TiO2-based phosphopeptide enrichment. Peptides were fractionated by high pH reversed-phase liquid chromatography. Briefly, the dried flow through from the pY1000 cartridge was reconstituted in 1 mL of high-pHRPLC solvent (10% Ammonium Formate in water pH 10) and fractionated by high-pHRPLC chromatography on a XBridge C18, 5 µm, 250 × 4.6 mm column (Waters Corporation, Milford, MA) by employing an increasing gradient of solvent B (10% Ammonium Formate in 90% Acetonitrile pH 10) on an Ultimate Plus by LC Packings HPLC with a flow rate of 250 µL/min. 1.5 min fractions (375 µL) over 90 minutes were collected for each separation for a total of 60 fractions. The high-pH fractions were then concatenated by pooling every 12th Fraction (1, 13, 25, 37, 49; then 2, 14, 26, 38, 50…12, 24, 36, 48, 60) to generate 12 pooled fractions (Fig. 1c). Due to the limited capacity of the XBridge column, each 20 mg sample was split in half and run as two subsequent separations and combine with the corresponding concatenated fractions such that the final output of the high-pHRPLC for each sample set was 12 pooled fractions that were lyophilized in a SpeedVac.

For phospho-peptide enrichment, each concatenated fraction was subjected to a TiO2 spin column following the vendors instructions (Thermo Scientific, # 88301). Briefly, each spin column was first washed with 10 µL of buffer A (80% acetonitrile in water) and buffer B (40% lactic acid in buffer A) each. The dried peptide fractions were suspended in 20 µL of buffer B. The peptide solution was applied to the spin columns and centrifuged at 1000 × g for 2 min. The pass through from the column was applied again to the column to increase the enrichment efficiency of phosphopeptides. Next, the column was washed with 20 µL each of buffer B and A respectively. The enriched phosphopeptides were eluted with 50 µL of elution buffer (30% ammonium hydroxide solution in water) twice. The eluted enriched phosphopeptides were dried using speed vac and stored at −80°C before further analysis as described previously.

High-pH reversed-phase liquid chromatography (high-pHRPLC) and TiO2-based phosphopeptide enrichment.
of 40% acetonitrile twice. The eluate was dried using speed vac and stored at 80 °C before LC-MS/MS analysis.

to 40% phase B (0.1% formic acid in acetonitrile, v/v) for 70 min, from 40% phase B to 85% phase B for 5 min, next

tion step was achieved using a varying mobile phase gradient from 95% phase A (0.1% formic acid in water, v/v)

keeping the same mobile phase composition for 5 min at 300 nL/min as described previously9.

The enriched phospho-serine/threonine peptides (dried form) were reconstituted in 40

µl of 50% acetonitrile in 0.1% TFA solution by spinning at 2000

µl of 0.1% TFA solution at

25

m, length 15 cm, C18

m, inner diameter of

100 μm, and 25 μm packed bed) from New Objective (Woburn, MA). The reconstituted peptide solution was

loaded onto the trap column at 2

µl/min in 0.1 formic acid in water (v/v) prior to the loading on IntegraFrit trap column (outer diameter of 360 μm, inner diameter of 100 μm, and 25 μm packed bed) from New Objective (Woburn, MA). The reconstituted peptide solution was loaded onto the trap column at 2 μl/min in 0.1 formic acid in water (v/v) for 10 min to desalt and concentrate the sample. For the analytical/chromatographic separation of phosphopeptides, the trap column was switched to align with the nanoLC separation column, an Acclaim PepMap 100 (inner diameter 75 μm, length 15 cm, C18 particle size of 3 μm, 100 Å of pore size) from Dionex-Thermo Fisher Scientific (Sunnyvale, CA). The peptide elution step was achieved using a varying mobile phase gradient from 95% phase A (0.1% formic acid in water, v/v) to 40% phase B (0.1% formic acid in acetonitrile, v/v) for 70 min, from 40% phase B to 85% phase B for 5 min, next keeping the same mobile phase composition for 5 min at 300 nL/min as described previously7.

Positive ion mode was used to operate the mass spectrometer using 4303 cycles for 90 min. 0.25 sec accumulation time and 350–1600 m/z window were used in each TOF-MS cycle. 20 information dependent acquisition (IDA) MS/MS-scans on the most intense candidate ions which had a minimum of 150 counts, were collected per cycle. An accumulation time of 0.05 sec and a mass tolerance of 100 ppm were used for the product ion scan.

Concentration of enriched phosphopeptides for LC-MS using StageTips. The enriched phosphopeptides were desalted/concentrated prior to LC-MS/MS analysis using custom made StageTips in the lab10. Empore High Performance Extraction C18 disks (AHO-2540 Phenomenex) were punched twice with P200 pipette tip and the N₂ gas pressure flow was used to transfer the punched C18 material into a P200 pipette tip (StageTip). Each Tip was washed with 40 μl of 50% acetonitrile in 0.1% TFA solution by spinning at 2000 × g for 5 min. Next, the membrane was prepared for peptide binding by washing with 40 μl of 0.1% TFA solution at 2000 × g for 5 min. The enriched phospho-serine/threonine peptides (dried form) were reconstituted in 40 μl of 0.1% TFA prior to the loading/binding on to the StageTip. The binding step was performed at 2000 × g for 10 min. The flow through of the load step was further applied to the StageTip columns (two sequential binding steps total). Post binding, the columns were washed with 40 μl of 0.1% TFA twice. The elution was performed with 40 μl of 40% acetonitrile twice. The eluate was dried using speed vac and stored at −80 °C before LC-MS/MS analysis.

Nano-LC-MS/MS Analysis. Nano-LC-MS/MS analyses on the phosphopeptide fractions were performed using a TripleTOF 5600+ MS (Sciex, Toronto, ON, Canada). Mass spectrometry was coupled with an Eksigent (Dublin, CA) nanoLC-ultra-system. Concentrated dried phosphopeptides were resolubilized in 0.1% formic acid in water (v/v) prior to the loading on IntegraFrit trap column (outer diameter of 360 μm, inner diameter of 100 μm, and 25 μm packed bed) from New Objective (Woburn, MA). The reconstituted peptide solution was loaded onto the trap column at 2 μl/min in 0.1 formic acid in water (v/v) for 10 min to desalt and concentrate the sample. For the analytical/chromatographic separation of phosphopeptides, the trap column was switched to align with the nanoLC separation column, an Acclaim PepMap 100 (inner diameter 75 μm, length 15 cm, C18 particle size of 3 μm, 100 Å of pore size) from Dionex-Thermo Fisher Scientific (Sunnyvale, CA). The peptide elution step was achieved using a varying mobile phase gradient from 95% phase A (0.1% formic acid in water, v/v) to 40% phase B (0.1% formic acid in acetonitrile, v/v) for 70 min, from 40% phase B to 85% phase B for 5 min, next keeping the same mobile phase composition for 5 min at 300 nL/min as described previously7.

Positive ion mode was used to operate the mass spectrometer using 4303 cycles for 90 min. 0.25 sec accumulation time and 350–1600 m/z window were used in each TOF-MS cycle. 20 information dependent acquisition (IDA) MS/MS-scans on the most intense candidate ions which had a minimum of 150 counts, were collected per cycle. An accumulation time of 0.05 sec and a mass tolerance of 100 ppm were used for the product ion scan.

Fig. 3 Phospho kinase arrays were used on the transduced BaF3 cells to validate the canonical JAK/STAT and MAPK/ERK signaling pathways downstream of the activated and non-activated receptors all as described in the Methods section. (a) BaF3 cells expressing normal and mutated G-CSFRs were serum starved for 6 hours and induced with 40 ng/mL G-CSF for 12.5 min and 90 min before the cells were lysed and the array membranes were treated with the lysates. The lysates treated membranes were exposed to primary and secondary antibody cocktail provided by the vendor and signal was measured with ChemiDoc™ touch imaging system for phospho-Stat5, phospho-Stat3, and phospho-Erk1/2 (panels: a–c respectively). The full images of the membrane blots are also provided as Supplementary Fig. 1. The quantitative data analysis was performed using Progenesis SameSpots software with the relative spot volumes plotted in the right panels for the indicated phosphorylation sites.
Mass spectrometric data analysis. The data generated by nano-LC-MS/MS (.wiff files) from the enriched phosphopeptides were further analyzed for protein identification and quantification using Protein Pilot software (version 5.0, revision 4769). Protein Pilot utilized the Paragon algorithm and was searched against a UniProt database of Mus musculus protein sequences. Each phospho-enriched raw MS data was processed using the SILAC specific settings in Protein Pilot: sample type (SILAC (Lys + 8, Arg + 10)), Cys Alkylation (Iodoacetamide), Digestion (Trypsin), instrument (Triple TOF 5600), and Special Factors (Phospho-emphasis). False Discovery Rate (FDR) was set as 0.05 with through ID as search effort. A combined search run was performed for the 12 MS runs (phospho-enriched samples from 12 high pH concatenated fractions) for phospho-serine/threonine peptides. The search results were generated as group files in an excel spreadsheet as a peptide summary report. A minimum of 95% confidence in identity (calculated by probability algorithm of Protein Pilot software) was used as a cut-off for phosphopeptides identification. Furthermore, sequence, modification, mass-to-charge ratio (m/z value), and charge (z) were as selection parameters for phosphopeptide data filtration as published previously.

Phosphoproteomic data processing using perl. A custom perl script was used to pre-process and normalize the phospho-proteomic dataset. This script utilized the raw data (search results generated by Protein Pilot as group files in a excel spreadsheet as peptide summary report), filtered out identifications at less than a 95% confidence level based on the Protein Pilot processing output, and normalized the peptides based on the median-normalized ratios of peptide intensities for receptor-activated vs. non-activated states (G-CSF treated vs. non-G-CSF treated). In cases where the same peptide was identified multiple times, the intensity data was averaged for that peptide. If a peptide was consistently detected in only one of the two (heavy or light) SILAC channels, log ratios of heavy to light peptide intensities were artificially set to plus or minus infinity. Furthermore, peptide ratios were normalized within replicates to have a median of 0 (i.e., no change between activated and non-activated states). Pearson correlation coefficients (r) between replicates were calculated to access the biological/technical reproducibility; these were shown to be very high at greater than 0.85 for all datasets. To understand the inter-relationship between the G-CSFR phosphorylation landscape between WT and mutant signaling, an unsupervised heatmap and clustering analysis was performed using R. The clustering analysis showed a reproducibility of each independent replicated by displaying their close cluster (Fig. 5a). For the final heatmap and clustering analysis (Fig. 5b), only those phospho-sites which were detected in both biological replicates were used.

Data Records
The raw data (.wiff files), group searched files (Protein Pilot.group files), and quant files [log2 (heavy/light) expression file: excel file format] resulting from phospho-Serine/Threonine analysis, have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchage.org) via the PRIDE partner repository. The extracted phospho-tyrosine dataset of the experimental work-flow involved here have been submitted independently and published. The raw data (.wiff files), group searched files (Protein Pilot.group files), and quant files [log2 (heavy/light) expression file: excel file format] of the phospho-tyrosine data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchage.org) via the PRIDE partner repository.
technical Validation
Sample preparation and quality control for G-CSFR signaling biology in the model system. Given that a global phosphoproteomics study needs large amount of starting material, a robust system was required which could be easily grown with high protein yield. The BaF3 cell system has been used as a workhorse to study G-CSFR signaling biology previously\(^2\)–\(^6\). Furthermore, they are easy to grow and endogenous levels of G-CSFR are not detectable by flow cytometry\(^8\),\(^12\), but they can be programmed to express receptors using lenti- and retroviral vectors\(^8\),\(^12\).

Based on all these properties, BaF3 cells were chosen to make an in vitro model system expressing empty vector, WT and mutated G-CSFRs (T618I and Q741x) respectively\(^8\). A retroviral transduction was performed with BaF3 cells and G-CSFRs expressing cells were further sorted by flow cytometry to isolate cell populations expressing physiologically relevant levels of WT or mutant receptors as illustrated in Fig. 1a. To ensure minimal variations due to the cellular background, all 4 receptor expressing cell types (empty vector, WT, T618I and Q741x) were generated by parallel transduction into a single BaF3 cell background as detailed elsewhere\(^8\).

Based on patient derived samples, an abnormal activation of STAT5, STAT3 and ERK 1/2 have been reported with mutations in G-CSFR when compared with the WT\(^5\),\(^6\). This includes a constitutive level of STAT3, STAT5 and ERK 1/2 activation in cells from patients with T618I mutation, and a prolonged phosphorylation of these regulatory proteins in patients with the Q741x truncation mutation\(^5\),\(^6\). To confirm whether our in vitro system using
receptors expressed on BaF3 cells can recapitulate similar signaling biology, the following validation experiments were performed. First, we performed an immunoblot analysis of a time course of G-CSF stimulation in the BaF3 model system clearly shows that the T618I mutation maintains a constitutive level of activation even after 6 hours of serum starvation, while receptor activation remains quiescent in WT and Q741x expressing cells. Secondly, the sustained or elevated activation of Stat3, Stat5 and Erk1/2 in the truncation mutation (Q741x) compared to the WT goes well beyond 2 hours as is reported for patient derived samples. Finally, evaluation of the G-CSF activation dynamics in the BaF3 model system using a phospho-kinase array method (Fig. 3 and Supplementary Fig. 1), also recapitulated the phosphorylated dynamics as reported for patient derived mutations in the G-CSFR. Thus collectively, by carefully designing the BaF3 system to express the WT, T618I or Q741x forms of G-CSFR at equal levels, a valid model system has been established that can be scaled up to levels sufficient for investigating the phosphorylation dynamics in the normal and disease-associated receptor mutations.

Quality check of phosphoproteomics data analysis. Each experimental condition of G-CSF induction was performed in two independent biological replicates. To measure the correlation between experimental findings, expression data were plotted using Pearson correlation analysis (Fig. 4). This analysis was done between each replicate and each time point (e.g., two independent biological replicate of WT group at 12.5 min—an early time point of G-CSF induction). The Pearson correlation analysis between each replicate showed a high reproducibility with coefficient (r) values all greater than 0.85 (Fig. 4). However, we did observe some outliers in the correlation analyses as depicted in Fig. 4. Most of these outliers stem from missing values among the replicates but even with these included, the correlations are still very high. Additionally, when evaluating the full dataset using unbiased heatmap as well as clustering analysis, each pairwise replicate clustered most closely to its biological replicate thus further validating the overall reproducibility of the dataset (Fig. 5a,b). We further filtered all identified phosphopeptides (>10,000) by removal of missing values (no imputation) and selection of only plus or minus log2 (1.5) (Heavy/Light) ratio to enriched the significant sites and their clustering pattern across G-CSFR phosphoproteome landscape (Fig. 5b). Collectively, upward of 1,000 phosphorylation site changes were observed after stringent filtering of the all identified phosphorylation sites.

In conclusion, the dataset presented passes both on the biological relevance of the model system (compared to known signaling dynamics from patient derived samples) and the reproducibility of the biological replicates for the SILAC, phospho-enrichment workflow. Hence the depth of the dataset with over 10,000 pS/pT phosphorylation sites detected and over 1,000 phosphorylation sites that showed at least a 50% change in stimulated versus non-stimulated conditions, provides a valuable dataset to be shared with the research community. An initial pass at cluster analysis begins to show unique clusters of phosphorylation among the variant group that will need to be exploited further (Fig. 5). We expect that these data can be mined further to advance the understanding of the dynamics of normal and variant G-CSFRs signaling in disease.

Code Availability
A custom code was written in perl programming language to parse and filter the phosphoproteomics data automatically, presented in this study. The code is provided as supplementary material (Supplementary File 1).

References
1. Dwivedi, P. et al. Phosphoproteomics analysis of normal and mutated granulocyte colony stimulating factor receptors. PRIDE. http://identifiers.org/pride.project:PXD009511 (2018).
2. Beekman, R. & Touw, I. P. G-CSF and its receptor in myeloid malignancy. Blood. 115, 5131–5136 (2010).
3. Touw, I. P. & Beekman, R. Severe congenital neutropenia and chronic neutrophilic leukemia: An intriguing molecular connection unveiled by oncogenic mutations in CSF3R. Haematologica. 98, 1480–1492 (2013).
4. Dwivedi, P. & Greis, K. D. Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Experimental Hematol. 46, 9–20 (2017).
5. Maxson, J. E. et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 368, 1781–1790 (2013).
6. Beekman, R. et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood. 119, 5071–5077 (2012).
7. Zhang, H. et al. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood. 116, 2462–2471 (2010).
8. Dwivedi, P. et al. Time resolved quantitative phospho-tyrosine analysis reveals Bruton’s Tyrosine kinase-mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors. Leukemia. 33, 75–87 (2019).
9. Wijeratne, A. B., Manning, J. R., Schultz, E. J. & Greis, K. D. Quantitative Phosphoproteomics Using Acetone-Based Peptide Labeling: Method Evaluation and Application to a Cardiac Ischemia/Reperfusion Model. J Proteome Res. 12(10), 4268–79 (2013).
10. Rappaport, J., Mann, M. & Ishihama, Y. Protocol for micro-purification enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nature Protocols. 2, 1896–1906 (2007).
11. Dwivedi, P. et al. Time resolved quantitative phospho-tyrosine analysis reveals Bruton’s Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors. PRIDE http://identifiers.org/pride.project:PXD009662 (2018).
12. Hunter, M. G. & Avalos, B. R. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood. 93, 440–446 (1999).

Acknowledgements
The authors thank Drs. Julia Maxson (Oregon Health Science University, Portland, OR) and Dr. Ivo Touw (Erasmus Medical Center, Rotterdam, The Netherlands) for insightful suggestions during the study. This article and our research work associated with G-CSFR are supported by several sources, including National Institutes of Health (NIH) Grant 1S10 RR027015-01 (KDG), the University of Cincinnati Millennium Scholars Fund (KDG), and the Cincinnati Children’s Hospital Research Foundation (KDG), Graduate Student Governance Association (GSGA) funding resources (PD), National Institutes of Health T32 ES007250-06 (DEM) as well as R01 CA196658 (HLG) and a grant from CancerFree Kids (HLG).
Author Contributions
P.D., D.E.M., H.L.G., and K.D.G. designed, performed, and analyzed all of the experiment. H.L.G. and K.D.G. provided intellectual inputs and directed the overall study. M.A. provided the CSF3R construct, BaF3 cells, IL3 and several reagents. M.W. played an instrumental role in the data sorting using custom scripts.

Additional Information
Supplementary Information is available for this paper at https://doi.org/10.1038/s41597-019-0015-8.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the metadata files associated with this article.

© The Author(s) 2019